Avalyn Pharma (AVLN) vs Ocular Therapeutix (OCUL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Avalyn Pharma is the larger company by market cap ($1.26 billion vs $1.23 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVLN | OCUL |
|---|---|---|
| Share price | $28.40 | $5.57 |
| Market cap | $1.26B | $1.23B |
| 1-day change | -1.05% | -4.95% |
| YTD return | — | -54.12% |
| 1-year return | — | -54.49% |
| 5-year return | — | -14.83% |
| EPS (TTM) | $-3.96 | $-1.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $51.95M |
| Revenue growth (YoY) | — | -18.47% |
| Net income (latest FY) | — | $-265.94M |
| Gross margin | — | 87.35% |
| Operating margin | — | -519.75% |
| Net margin | — | -511.90% |
| 52-week high | $40.17 | $16.44 |
| 52-week low | $22.24 | $5.54 |
| Distance from 52-week high | -29.30% | -66.12% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +114.79% | +361.94% |
| Average volume | 352.95K | 3.03M |
| Shares outstanding | 44.52M | 220.02M |
| Employees | 56 | 325 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Avalyn Pharma
AVLN stock →Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees
About Ocular Therapeutix
OCUL stock →Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 325 employees
AVLN vs OCUL FAQ
Which is bigger, Avalyn Pharma or Ocular Therapeutix?
Avalyn Pharma (AVLN) is larger, with a market capitalization of $1.26B compared with $1.23B for Ocular Therapeutix (OCUL).
Are Avalyn Pharma and Ocular Therapeutix in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.